Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.75.

Several brokerages recently weighed in on MSLE. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st. Guggenheim began coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a report on Thursday, July 9th. Finally, HC Wainwright raised their price objective on Satellos Bioscience from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th.

Satellos Bioscience Stock Performance

Satellos Bioscience stock opened at $10.03 on Friday. The company has a 50 day moving average price of $7.85. Satellos Bioscience has a 1-year low of $4.84 and a 1-year high of $13.39. The stock has a market cap of $209.03 million, a PE ratio of -6.27 and a beta of 1.51.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). On average, research analysts forecast that Satellos Bioscience will post -1.69 earnings per share for the current year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.